CD274 and neoplasm: To this end, C57BL/6 mice harbouring ID8-Trp53−/−Cxcl9+ or Control tumours were randomised to receive either anti-PD-L1 antibody or an IgG2b isotype control antibody twice a week (Fig. 2a).